An Open-label, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease

Trial Profile

An Open-label, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Adipose-derived-autologous-stem-cell-therapy-U.S.-Stem-Cell (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors U.S. Stem Cell
  • Most Recent Events

    • 15 Mar 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 28 Apr 2015 According to the the ClinicalTrial record, planned end date changed from 1 Jan 2016 to 1 Jan 2017.
    • 28 Apr 2015 According to the the ClinicalTrial record, planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top